Skip to main content
SpringerLink
Log in

Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

In order to evaluate serotonin (5-HT) function in panic disorder, a double blind placebo controlled study was conducted with ritanserin, a specific 5-HT2 receptor antagonist, and fluvoxamine, a selective 5-HT reuptake inhibitor, in 60 patients with panic disorder. Patients were treated for 8 weeks with 150 mg fluvoxamine, 20 mg ritanserin or placebo; these dose levels were reached after 1 week. In addition, as an index of 5-HT function in panic disorder, plasma concentration of β-endorphin, cortisol and 5-hydroxyindolacetic-acid (5-HIAA) were measured. Furthermore, 5-HT uptake in blood platelets was assessed. Noradrenergic function was assessed by measuring plasma MHPG concentration. In addition, plasma melatonin concentration was measured. Treatment with fluvoxamine resulted in a profound reduction in the number of panic attacks, followed by a decrease in avoidance behavior. Treatment with ritanserin appeared to be ineffective. During treatment no significant changes were observed in plasma concentrations of β-endorphin, cortisol, 5-HIAA and MHPG. With respect to 5-HT kinetics in blood platelets, a substantial increase in Km was observed after treatment with fluvoxamine, whereas Vmax decreased. After treatment with fluvoxamine, plasma concentration of melatonin was significantly increased, which suggests that melatonin synthesis is in part under serotonergic control. The findings of the present study do not support the hypothesis that 5-HT2 receptors are supersensitive in patients suffering from panic disorder, but allow no conclusions about the involvement of other 5-HT receptor subtypes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders. DSM-III

  • American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders. DSM-III-R

  • Bressa GM, Marini S, Gregori S (1987) Serotonin S2 receptors blockade and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam. Int J Clin Pharmacol Res 7:111–119

    PubMed  Google Scholar 

  • Carr DB, Sheehan DV, Surmon OS et al. (1986) Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy. Am J Psychiatry 143:483–494

    PubMed  Google Scholar 

  • Cella S, Penalva A, Locatelli V, Novelli A, Cocchi D, Müller EE (1983) Neuroendocrine studies with fluvoxamine: animal data. Br J Clin Pharmacol 15:357S-363S

    PubMed  Google Scholar 

  • Ceulemans DLS, Hoppenbrouwers MLJA, Gelders YG et al. (1985) The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind, placebo-controlled study versus lorazepam. Pharmacopsychiatry 18:303–305

    PubMed  Google Scholar 

  • Chaput Y, Blier P, De Montigny C (1988) Acute and long-term effects of antidepressant serotonin (5-HT) reuptake blockers on the efficacy of 5-HT neurotransmission: electrophysiological, studies in the rat central nervous system. Adv Biol Psychiatry 17:1–17

    Google Scholar 

  • Charney DS, Heninger GR (1985a) Noradrenergic function and the mechanism of action of anti-anxiety treatment. I. The effect of long-term alprazolam treatment. Arch Gen Psychiatry 42:458–467

    PubMed  Google Scholar 

  • Charney DS, Heninger GR (1985b) Noradrenergic function and the mechanisms of action of anti-anxiety treatment. II. The effect of long-term imipramine treatment. Arch Gen Psychiatry 42:473–481

    PubMed  Google Scholar 

  • Charney DS, Heninger GR (1986) Abnormal regulation of noradrenergic function in panic disorders. Arch Gen Psychiatry 43:1042–1054

    PubMed  Google Scholar 

  • Charney DS, Heninger GR, Breier A (1984) Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41:751–763

    PubMed  Google Scholar 

  • Charney DS, Woods SW, Goodman WK et al. (1987) Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology 92:14–24

    Article  PubMed  Google Scholar 

  • Claassen V (1983) Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol 15:349S-355S

    PubMed  Google Scholar 

  • Colpaert FC, Meert TF, Niemegeers CJE et al. (1985) Behavioural and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rat. Psychopharmacology 86:45–54

    Article  PubMed  Google Scholar 

  • Demisch K, Demisch L, Bochnik HJ et al. (1986) Melatonin and cortisol increase after fluvoxamine. Br J Clin Pharmacol 22:620–622

    PubMed  Google Scholar 

  • Demisch K, Demisch L, Nichelsen T et al. (1987) The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamine. J Neural Transm 68:257–270

    Article  PubMed  Google Scholar 

  • Den Boer JA, Westenberg HGM (1988) Effect of serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3:59–74

    Google Scholar 

  • Den Boer JA, Westenberg HGM (1990) Behavioral, neuroendocrine and biochemical effects of 5-HTP administration in panic disorder. Psychiatry Res 31:267–278

    Article  PubMed  Google Scholar 

  • Den Boer JA, Westenberg HGM, Kamerbeek WDJ et al. (1987) Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 2:21–32

    PubMed  Google Scholar 

  • Dominguez RA, Goldstein BJ, Jacobson AF et al. (1985) A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. J Clin Psychiatry 46:84–87

    PubMed  Google Scholar 

  • Evans L, Moore G (1981) The treatment of phobic anxiety by zimeldine. Acta Psychiatr Scand 63 (S290):342–345

    Google Scholar 

  • Evans L, Kenardy J, Schneider P et al. (1986) Effects of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo. Acta Psychiatr Scand 73:49–53

    PubMed  Google Scholar 

  • Geller I, Blum K (1970) The effects of 5-HTP on para-chlorophenylalanine (p-CPA) attenuation of “conflict” behavior. Eur J Pharmacol 9:319–324

    PubMed  Google Scholar 

  • Gloger S, Grunhaus L, Birmacher B et al. (1981) Treatment of spontaneous panic attacks with chlomipramine. Am J Psychiatry 138:1215–1217

    PubMed  Google Scholar 

  • Graeff FG, Silveira Filho NG (1978) Behavioral inhibition induced by electrical stimulation of the median raphe nucleus of the rat. Physiol Behav 21:477–484

    PubMed  Google Scholar 

  • Hamik A, Peroutka J (1989)l-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 25:569–575

    Article  PubMed  Google Scholar 

  • Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55

    PubMed  Google Scholar 

  • Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296

    PubMed  Google Scholar 

  • Idzikowski C, Cowen PJ, Nutt D et al. (1987) The effects of chronic ritanserin treatment on sleep and the neuroendocrine response tol-tryptophan. Psychopharmacology 93:416–420

    Article  PubMed  Google Scholar 

  • Kahn RS, Westenberg HGM, Verhoeven WMA et al. (1987) Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 2:33–45

    PubMed  Google Scholar 

  • Kahn RS, Asnis GM, Wetzler S et al. (1988) Neuroendocrine evidence for a serotonin receptor supersensitivity in panic disorder. Psychopharmacology 96:360–364

    Article  PubMed  Google Scholar 

  • Kelly D, Guirguis W, Frommer E et al. (1970) Treatment of phobic states with antidepressants. Br J Psychiatry 116:387–398

    PubMed  Google Scholar 

  • Klein DF (1964) Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 5:397–408

    Article  Google Scholar 

  • Klein DF (1980) Anxiety reconceptualized. Comp Psychiatry 21:411–427

    Article  Google Scholar 

  • Klok CJ, Brouwer GJ, Van Praag HM et al. (1981) Fluvoxamine and clomipramine in depressed patients: a double-blind clinical study. Acta Psychiatr Scand 64:1–11

    PubMed  Google Scholar 

  • Kockzkas S, Holmberg G, Wedin L (1981) A pilot study of the effect of 5-HT uptake inhibitor, zimeldine, on phobic anxiety. Acta Psychiatr Scand 63 (S290):328–341

    Google Scholar 

  • Levin AP, Doran AP, Liebowitz MR et al. (1987) Pituitary adrenocortical unresponsiveness in lactate-induced panic. Psychiatry Res 21:23–32

    PubMed  Google Scholar 

  • Lewis DA, Noyes R, Coryell W et al. (1985) Tritiated imipramine binding to platelets is decreased in patients with agoraphobia. Psychiatry Res 16:1–9

    Article  PubMed  Google Scholar 

  • Leysen JE, Gommeren W, van Gompel P (1985) Receptor binding properties in vitro and in vivo of ritanserin: a very potent and long-acting 5-HT2 antagonist. Mol Pharmacol 27:600–611

    PubMed  Google Scholar 

  • Liebowitz MR, Gorman JM, Fyer A et al. (1986) Possible mechanisms for lactate's induction of panic. Am J Psychiatry 143:495–502

    PubMed  Google Scholar 

  • Marks IM, Matthews AM (1979) Brief standard self-rating for phobic patients. Behav Res Ther 17:263–267

    Article  PubMed  Google Scholar 

  • Mavissakalian M (1986) The fear questionnaire: a validity study. Behav Res Ther 24:83–85

    Article  PubMed  Google Scholar 

  • Mavissakalian M (1987) Initial depression and response to imipramine in agoraphobia. J Nerv Ment Dis 175:358–361

    PubMed  Google Scholar 

  • Mavissakalian M, Perel JM, Michelson L (1984) The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia. J Clin Psychopharmacol 4:36–40

    PubMed  Google Scholar 

  • McIntyre IM, Marriott PF, Jefferys D et al. (1986) Melatonin in panic disorder. Biol Psychiatry 21:1438–1441

    Article  PubMed  Google Scholar 

  • Moret C, Briley M (1989) Subsensitivity of the terminal 5-HT autoreceptorfollowing chronic administration with citalopram. In: International Symposium on Serotonin from Cell Biology to Pharmacology and Therapeutics, Florence, Italy, p 90

  • Mueller EA, Murphy DL, Sunderland T (1985) Neuroendocrine effects ofm-Chlorophenylpiperazine, a serotonin agonist in humans. J Clin Endocrinol Metab 61:1179–1184

    PubMed  Google Scholar 

  • Norman TR, Judd FK, Gregory M et al. (1986) Platelet serotonin uptake in panic disorder. J Affective Disord 11:69–72

    Article  Google Scholar 

  • Nutt DJ, Fraser S (1987) Platelet binding studies in panic disorder. J Affective Disord 12:7–11

    Article  Google Scholar 

  • Peroutka SJ, Snyder SH (1980) Long-term antidepressant treatment decreases spiroperodol-labelled serotonin receptor binding. Science 210:88–90

    PubMed  Google Scholar 

  • Petraglia F, Penalva A, Genazzani AR et al. (1982) Stimulation of β-endorphin and β-lipotropin release from the anterior but not the neurointermediate pituitary lobe in the rat after acute administration of serotonin-acting drugs. Life Sci 31:2809

    Article  PubMed  Google Scholar 

  • Petraglia F, Facchinetti F, Martignoni E et al. (1984) Serotonergic agonists increase plasma levels of β-endorphin and β-lipotropin in humans. J Clin Endocrinol Metab 59:1138–1142

    PubMed  Google Scholar 

  • Richelson E, Nelson A (1984) Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230:94–102

    PubMed  Google Scholar 

  • Schneider LS, Munjack D, Severson JA et al. (1987) Platelet [3H]imipramine binding in generalized anxiety disorder, panic disorder, and agoraphobia with panic attacks. Biol Psychiatry 22:59–66

    PubMed  Google Scholar 

  • Spielberger CD (1980) Test manual for the State-Trait Anxiety Inventory-STAI from Y. Consulting Psychologists Press, Palo Alto

    Google Scholar 

  • Stein L, Wise CD, Berger BD (1973) Anti-anxiety action of benzodiazepines: decrease in activity of serotonin neurons in the punishment system. In: Garattini S, Mussine E, Randall LO (eds) The benzodiazepines. Raven Press, New York, pp 299–326

    Google Scholar 

  • Thijssen JHH, Van den Berg JHM, Adlercreutz J (1980) The determination of cortisol in human plasma: evaluation and comparison of seven assays. Clin Chim Acta 100:39–46

    Article  PubMed  Google Scholar 

  • Tye NC, Iversen SA, Green SA (1979) The effects of benzodiazepine and serotonergic manipulations on punished responding. Neuropharmacology 18:689–695

    Article  PubMed  Google Scholar 

  • Tyrer P, Candy J, Kelly D (1973) A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia 32:237–254

    Article  PubMed  Google Scholar 

  • Uhde TW, Berrettini WH, Roy-Byrne PP et al. (1987) Platelet [3H]imi-pramine binding in patients with panic disorder. Biol Psychiatry 22:52–58

    PubMed  Google Scholar 

  • Van Nueten JM, Schuurkes JAJ, De Ridder WJE et al. (1986) Comparative pharmacological profile of ritanserin and ketanserin. Drug Dev Res 8:187–195

    Article  Google Scholar 

  • Van der Ploeg HM, Defares PB, Spielberger CD (1981) Handleiding bij de zelf-beoordelingsvragenlijst. Swets and Zeitlinger BV, Lisse

    Google Scholar 

  • Westenberg HGM, Den Boer JA (1989) Serotonin function in panic disorder: effect ofl-5-hydroxytryptophan in patients and controls. Psychopharmacology 98:283–285

    PubMed  Google Scholar 

  • Willner P (1985) Antidepressants and serotonergic transmission: an integrative review. Psychopharmacology 85:387–404

    Article  PubMed  Google Scholar 

  • Wong DT, Reid LR, Bymaster FP, Threlkeld PG (1985) Chronic effects of fluoxetine, a selective inhibitor of serotonin uptake, on neurotransmitter receptors. J Neural Transm 64:251–269

    Article  PubMed  Google Scholar 

  • Wood K, Swade C, Abou-Saleh M et al. (1983) Drug plasma levels and platelet 5-HT uptake inhibition during long-term treatment with fluvoxamine or lithium in patients with affective disorders. Br J Clin Pharmacol 16:365S-368S

    PubMed  Google Scholar 

  • Zitrin CM, Klein DF, Woerner MG et al. (1983) Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 40:125–138

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Psychiatry, University Hospital Utrecht, P.O. Box 85500, NL-3508 GA, Utrecht, The Netherlands

    Johan A. Den Boer & H. G. M. Westenberg

Authors
  1. Johan A. Den Boer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. G. M. Westenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Den Boer, J.A., Westenberg, H.G.M. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 102, 85–94 (1990). https://doi.org/10.1007/BF02245749

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02245749

Key words

Search

Navigation